Influenza A virus H7N9 vaccine - Novavax
Alternative Names: A (H7N9) vaccine - Novavax; A(H7N9) influenza vaccine candidate - Novavax; H7N9 Virus-Like Particle (VLP) Influenza vaccine (recombinant) - Novavax; H7N9 VLP vaccine - Novavax; Monovalent VLP influenza H7N9 vaccine - Novavax; Pandemic H7N9 + Matrix-M™ influenza vaccine; Pandemic H7N9 Influenza VLP vaccineLatest Information Update: 28 Sep 2021
Price :
$50 *
At a glance
- Originator Novavax
- Class Influenza A virus H7N9 vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus H7N9 subtype
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-I for Influenza A virus H7N9 subtype (Prevention) in Australia (IM)
- 28 Sep 2021 Discontinued - Phase-II for Influenza A virus H7N9 subtype (Prevention) in USA (IM)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Influenza-A virus H7N9 subtype(Prevention) in Australia (IM, Injection)